Benitec Biopharma Inc
NASDAQ:BNTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PW Medtech Group Ltd
HKEX:1358
|
CN |
|
Shenzhen Farben Information Technology Co Ltd
SZSE:300925
|
CN |
|
G
|
Green Thumb Industries Inc
CNSX:GTII
|
US |
|
N
|
Newonder Special Electric Co Ltd
SZSE:301120
|
CN |
|
Stemmer Imaging AG
XETRA:S9I
|
DE |
|
B
|
Best Food Holding Company Ltd
HKEX:1488
|
HK |
|
Sona BLW Precision Forgings Ltd
NSE:SONACOMS
|
IN |
Benitec Biopharma Inc
Other Equity
Benitec Biopharma Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Benitec Biopharma Inc
NASDAQ:BNTC
|
Other Equity
-$750k
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$1.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$31m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
$8.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
-$49.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
$77.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
21%
|
CAGR 10-Years
25%
|
|
Benitec Biopharma Inc
Glance View
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 14 full-time employees. The company went IPO on 2012-07-11. The firm is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The firm's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The firm's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
See Also
What is Benitec Biopharma Inc's Other Equity?
Other Equity
-750k
USD
Based on the financial report for Dec 31, 2025, Benitec Biopharma Inc's Other Equity amounts to -750k USD.
What is Benitec Biopharma Inc's Other Equity growth rate?
Other Equity CAGR 5Y
14%
Over the last year, the Other Equity growth was -9%. The average annual Other Equity growth rates for Benitec Biopharma Inc have been 6% over the past three years , 14% over the past five years .
